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Background. von Willebrand’s disease (VWD) is an
autosomally inherited bleeding disorder caused by a defi-
ciency or abnormality of von Willebrand factor (VWF). VWF
is a multimeric adhesive protein which plays an important
role in primary hemostasis by promoting platelet adhesion
to the subendothelium at sites of vascular injury and
platelet-platelet interactions in high shear-rate conditions.
It is also the carrier of factor VIII (FVIII), thus indirectly
contributing to the coagulation process. VWD has a preva-
lence of about 1% in the general population, but the fig-
ure for clinically relevant cases is lower (about 100/mil-
lion inhabitants). Bleeding manifestations are heteroge-
neous: mucosal bleeding is typical of all VWD cases but
hemarthrosis and hematomas may also be present when
FVIII levels are low.
Information sources. Most cases appear to have a
partial quantitative deficiency of VWF (type 1 VWD) with
variable bleeding tendency, whereas qualitative variants
(type 2 VWD), due to a dysfunctional VWF, are clinically
more homogeneous. Type 3 VWD is rare and the patients
have a moderate to severe bleeding diathesis because of
the virtual absence of VWF, and a recessive pattern of
inheritance. The diagnosis of VWD, especially type I, may
be difficult, because the laboratory phenotype is highly
heterogeneous and is confounded by the fact that factors
outside the VWF gene (e.g., blood group) influence VWF
levels. An array of tests is usually required to character-
ize the VWD types of the disorder and establish the best
treatment modality.
Conclusions. The aim of treatment is to correct the
dual defect of hemostasis, i.e. abnormal coagulation
expressed by low levels of FVIII and abnormal platelet
adhesion expressed by the prolonged bleeding time (BT).
Desmopressin (DDAVP)  is the treatment of choice for
type 1 VWD because it corrects the FVIII/VWF levels and
the prolonged BT in the majority of cases. In type 3 and
in severe forms of  type 1 and 2 VWD, DDAVP is not effec-
tive and for these patients plasma virally-inactivated con-
centrates containing FVIII and VWF are the mainstay of
treatment. These concentrates are clinically effective and
safe, although they do not always correct the BT.
Key words: von Willebrand factor, congenital von Wille-
brand’s disease, genetic and molecular diagnosis, desmo-
pressin, factor VIII/von Willebrand factor concentrates.
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When, in 1926, Erik von Willebrand  described anovel bleeding disorder in a large family fromFoglo on the islands of Aland in the Gulf of
Bothnia, he provided an impressive and exhaustive
description of the disorder’s clinical and genetic fea-
tures. Unlike hemophilia, the epitome of inherited
bleeding disorders, both sexes were affected, and
mucosal bleeding was the dominant symptom. A pro-
longed bleeding time (BT) with a normal platelet count
was the most important laboratory abnormality and a
functional disorder of the platelets associated with a
systemic lesion of the vessel wall was suggested as a
possible cause of the disorder. However, he called the
disease hereditary pseudohemophilia. To further com-
plicate the issue, some authors subsequently called the
disorder vascular hemophilia.
Only in the 1950s, was it demonstrated that the pro-
longed BT in these patients was associated with reduced
factor VIII (FVIII), but we had to wait until the 1970s to
clarify that the deficiency of a new factor, called von
Willebrand factor and different from FVIII, was actual-
ly responsible for the disease. Surprisingly, the reduction
of this factor caused low FVIII, pointing to the close
relationships between the two proteins. In the 1980s,
the cloning of the VWF gene set the basis for unravel-
ing the molecular causes of the disorder. 
The history of von Willebrand’s disease (VWD) has
been the subject of recent reviews.1 In this article we
discuss the progress and the problems of diagnosis and
treatment of VWD today, in the year 2003, 77 years
after the original description by Erik von Willebrand.
The von Willebrand factor
Von Willebrand’s disease is the most frequent inher-
ited bleeding disorder and is due to a deficiency and/or
abnormality of von Willebrand factor (VWF). VWF is
synthesized by endothelial cells and megakaryocytes.
The gene coding for VWF has been cloned and located
at chromosome 12p13.2. It is a large gene composed of
about 178 kilobases and containing 52 exons. A non-
coding, partial, highly homologous pseudogene has
been identified in chromosome 22.2 The pseudogene
spans the gene sequence from exon 23 to 34.2
The primary product of the VWF gene is a 2,813 amino
acid protein made of a signal peptide of 22 amino acids
(also called a pre-peptide), a large pro-peptide of 741
amino acids and a mature VWF molecule containing
2,050 amino acids. In keeping with a recently proposed
nomenclature,3 numbering starts from the first amino
acid of the signal peptide, so 764 is the first amino acid
of the mature protein. Different protein regions, corre-
sponding to four types of repeated domains (D1, D2, D’,
D3, A1, A2, A3, D4, B, C1, C2) of cDNA, are responsible
for the different binding functions of the molecule (Fig-
ure 1). Mature VWF is the result of ordered intra-
cellular processing, leading to the storage and/or
secretion of a heterogeneous array of multimeric
multidomain glycoproteins, collectively referred to
as VWF.
Purified VWF visualized by electron microscopy
appears either as a filamentous structure with a
diameter of 2-3 nm and a length of up to 1300 nm,
close to the diameter of platelets, or as a loosely
coiled molecule with a diameter of 2-300 nm.4 The
building block of VWF multimers is a dimer made
up of two single-chain pro-VWF molecules, joined
through disulphide bonds within their C-terminal
region. This reaction occurs after cleavage of the
signal peptide and the subsequent translocation
and glycosylation of the precursor molecules into
the endoplasmic reticulum. The pro-VWF dimers
are then transported to the Golgi apparatus where,
after further post-translational modifications
including processing of high mannose oligosac-
charides, they are polymerized into very large mol-
ecules up to a molecular weight of 20,000 × 103
through disulphide bonds connecting the two N-
terminal ends of each dimer. After polymerization,
pro-VWF multimers move to the trans-Golgi net-
work where the VWF pro-peptide (also called VWF:
AgII) is cleaved off by a paired amino acid-cleav-
ing enzyme (PACE or furin) and remains, at least
within the cell, non-covalently associated with
VWF.  VWF pro-peptide is secreted into the circu-
lation together with native VWF and can be mea-
sured in plasma with specific antibodies.5
VWF is secreted from the cell along a constitutive
and a regulated pathway. The latter is used for rapid
stimuli-induced release (e.g. by desmopressin
through its binding on the vasopressin V2 receptor
of endothelial cells) from specialized storage
organelles of endothelial cells known as Weibel-
Palade bodies. Only Weibel-Palade bodies or α-
granules in platelets contain fully processed and
functional VWF with unusually large multimers,
which are usually not found in circulation. Indeed,
a specific plasma protease acts on VWF multimers
released from the cell, cleaving the VWF subunit at
the bond between Tyr1605 and Met1606 (Tyr842
and Met843 of the mature subunit), reducing the
size of plasma VWF and creating the full spectrum
of circulating VWF species, ranging from the single
dimer to about 20 dimers in each VWF multimer.6
Regulatory cis-acting elements in the immediate
upstream promoter region and first exon of the
VWF gene and more complex transcriptional reg-
ulation pathways have been identified, which are
responsible for cell and vascular bed-specific
expression of VWF.7 Besides being found in
endothelial cells, megakaryocytes and platelets,
VWF is present in the subendothelial matrix, where
it is bound, through specific regions in its A1 and
A3 domains, to different types of collagen.
VWF has two major functions in hemostasis.
First, it is essential for platelet-subendothelium
adhesion and platelet-to-platelet interactions as
well as platelet aggregation in vessels in which
rapid blood flow results in elevated shear stress, a
function partially explored in vivo by measuring the
BT. Adhesion is promoted by the interaction of a
region of the A1 domain of VWF with GpIbα on
platelet membrane. It is thought that high shear
stress activates the A1 domain of the collagen-
bound VWF by stretching VWF multimers into their
filamentous form. Furthermore GPIbα and VWF are
also necessary for platelet-to-platelet interac-
tions.8 The interaction between GPIbα and VWF can
be mimicked in platelet–rich plasma by addition of
the antibiotic ristocetin, which promotes the bind-
ing of VWF to GPIbα of fresh or formalin-fixed
platelets. The A1 domain has been crystallized in
complex with the Fab fragment of the function-
blocking antibodies NMC-4. The solved structure at
2.2 Angstrong resolution provides information not
only on the VWF residues interacting with the anti-
body, but also on the possible location of the GPI-
bα binding site.7,8 Aggregation of platelets within
the growing hemostatic plug is promoted by the
interaction with a second receptor on platelets,
GPIIb-IIIa (or integrin αIIbβ3), once activated, binds
to VWF and fibrinogen, recruiting more platelets
into a stable plug. Both these binding activities of
VWF are highly expressed in the largest VWF mul-
timers.
Second, VWF is the specific carrier of factor VIII
(FVIII) in plasma. VWF protects FVIII from prote-
olytic degradation, prolonging its half-life in cir-
culation and efficiently localizing it at the site of
vascular injury. Each VWF monomer has one bind-
ing domain, located in the first 272 amino acids of
the mature subunit (D’ domain) which can bind one
FVIII molecule, in vivo; however only 1-2 % of
available monomers are occupied by FVIII.9 This
explains why high molecular weight multimers are
not essential for the carrier function of FVIII,
although one would expect molecules of the high-
est molecular weight to be most effective in local-
izing FVIII at the site of vascular injury. In any case
any change in plasma VWF level is usually associ-
ated with a concordant change in FVIII plasma con-
centration.
Classification of von Willebrand’s disease
For further understanding of the terminology
currently used, Table 1 summarizes the factor
VIII/VWF complex nomenclature, as recommended
by the International Society of Thrombosis and
Hemostasis. Basically, the revised classification of
VWD identifies two major categories, character-
ized by quantitative (types 1 and 3) or qualitative
(type 2) VWF defects (Table 2). A partial quantita-
tive deficiency of VWF in plasma and/or platelets
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identifies type 1 VWD, whereas type 3 VWD is
marked by the total absence or only trace amounts
of VWF in plasma and platelets.10 Type 1 is easily
distinguished from type 3 by the milder VWF defi-
ciency (usually in the range of 20-40 U/dL), the
autosomal dominant inheritance pattern and the
presence of milder bleeding symptoms. Four type 2
VWD subtypes have been identified, reflecting dif-
ferent pathophysiologic mechanisms.10 Type 2A and
2B VWD are marked by the absence of high mole-
cular weight VWF multimers in plasma; in type 2B,
there is increased affinity for platelet GPIbα.
The identification of qualitatively abnormal vari-
ants with decreased platelet-dependent function
and the presence of normal multimers on gel elec-
trophoresis has led the addition of a new subtype,
called 2M. If this definition is followed and more
stringent criteria are applied to VWD diagnosis,
many cases previously identified as type 1 VWD
should now be classified as type 2M VWD because
they are caused by single missense mutations
affecting VWF function but not its multimeric
structure and assembly (see later). Furthermore,
type 2N (Normandy) also shows a full array of mul-
timers since the defect lies in the N-terminal region
of the VWF where the binding domain for factor
VIII resides.11 The subtype is phenotypically identi-
fied only by the FVIII/VWF binding test (see later). 
Genetics and molecular biology of
von Willebrand’s disease
Cloning the VWF gene has allowed the identifi-
cation of several suitable restriction fragment
length polymorphisms (RFLP) which demonstrate
the co-segregation of VWD phenotype with haplo-
type-specific RFLP patterns in family members of
different kindred with VWD.12
Knowledge of the crucial segments of VWF
involved in the interaction with GPIbα initially
prompted the fruitful search for mutations in exon
28 of the VWF gene which encodes for the A1 and
A2 domains of mature VWF as reported in Figure
1.12 The search for mutations has been extended to
additional VWF exons encoding for the other func-
tional domains of VWF. The most frequent muta-
tions reported in types 2A, 2B, 2M, 2N are listed in
Table 3 according to the specific VWF domains and
are currently updated in the web site organized on
behalf of the Scientific Standardization Committee
of the International Society of Thrombosis and
Haemostasis (www.shef.ac.uk/vwf).
Most type 2A cases are due to missense muta-
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Table 1. Recommended nomenclature of factor VIII/von
Willebrand factor complex.
Factor VIII
Protein VIII
Antigen VIII:Ag
Function VIII:C 
Von Willebrand factor
Mature Protein VWF
Antigen VWF:Ag
Ristocetin cofactor activity VWF:RCo
Collagen binding capacity VWF:CB
Factor VIII binding capacity VWF:FVIIIB
Table 2. Classification of von Willebrand’s disease (modified
from Sadler).10
Quantitative deficiency of VWF
Type 1. Partial quantitative deficiency of VWF
Type 3. Virtually complete deficiency of VWF
Qualitative deficiency of VWF
Type 2. Qualitative deficiency of VWF
A) Type 2A. Qualitative variants with decreased platelet-dependent function
associated with the absence of high-molecular-weight VWF multimers.
B) Type 2B. Qualitative variants with increased affinity for platelet GPIbα.
C) Type 2M. Qualitative variants with decreased platelet-dependent function
not caused by the absence of high-molecular-weight VWF multimers.
D) Type 2N. Qualitative variants with markedly decreased affinity for factor VIII.
Figure 1. Schematic representation of the VWF gene locat-
ed in chromosome 12 together with the pseudogene in chro-
mosome 22. The main exons are indicated with the number
of base pairs from 5’ to 3’ (above). DNA domain structure
and pre-pro-VWF polypeptide: the pre-pro-VWF is indicated
with amino acids numbered from the amino- (aa 1) to car-
boxy-terminal portions (aa 2813) of VWF. Note the impor-
tant CK and D3 domains for formation of VWF dimers and
multimers (below). The native mature subunit of VWF, after
cleaving of the pre-pro VWF, is described with its function-
al domains: the VWF binding sites for factor VIII (D’ and
D3), GPIbα, botrocetin, heparin, sulfatide, collagen (A1),
collagen (A3) and the RGD sequence for binding to αIIbβ3.
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tions in the A1 domain, with R1597W or Q or Y and
S1506L accounting for about 60%.12,13 Expression
experiments have shown two possible mecha-
nisms.14 Group I mutations show impaired secretion
of high molecular weight multimers, due to sec-
ondary defective intracellular transport. Group II
mutations show normal synthesis and secretion of
a VWF which is probably more susceptible to in
vivo proteolysis (Table 3). The majority of type 2B
cases are due to missense mutations in the A1
domain, about 90 % being caused by R1306W,
R1308C, V1316M and R1341Q mutations.12,13 A few
heterogeneous mutations are responsible for type
2M cases and are also located within the A1
domain.12,13 Therefore most mutations are
expressed and the mutated recombinant VWF have
been compared with others found within the same
domain (Table 3).
A recurrent mutation in type 2M Vicenza has
been recently reported in families from Europe
(R1205H); it associated with a second nucleotide
change (M740I) exclusively identified in some fam-
ilies from the Vicenza area.15,16 Missense mutations
in the FVIII-binding domain at the amino-terminal
portion of VWF are responsible for type 2N.17 The
R854Q mutation is the most frequent and has
found in about 2% of the Dutch population.18 This
mutation may cause symptoms only in homozy-
gous or compound heterozygous states. Identifi-
cation of the type 2N mutation, which is suspect-
ed in case of a marked reduction of FVIII in com-
parison to VWF and is confirmed by the FVIII/VWF
binding test, is important for genetic counseling to
exclude the state of carrier for hemophilia A.11
The inheritance of type 1 VWD is usually auto-
somal dominant, with variable phenotype and pen-
etrance. Despite its high prevalence, the precise
genetic cause of type 1 VWD is still elusive in most
cases, especially those with a mild phenotype.
Many type 1 VWD cases might be compound het-
erozygotes, producing an apparent dominant
transmission18 or alternatively, the mutated allele
is negatively influenced by the effects of gene(s)
outside the VWF gene and by other non-genetic
factors contributing to the expression of a bleed-
ing phenotype. In rare cases it is caused by frame-
shifts, nonsense mutations, or deletions that over-
lap those identified in type 3 VWD.12 In a few cas-
es with high penetrance, missense mutations have
been described, for example of a cysteine in the
D3 domain, resulting in a dominant negative mech-
anism.19,20 In this case, mutant wild-type het-
erodimers are retained in the endoplasmic reticu-
lum and only wild type homodimers are released
into the circulation.19
The variable penetrance and severity of type 1
VWD may indeed be explained in some cases by
the inheritance of two different VWD alleles.18,21
Co-inheritance of R854Q mutation with a null
mutation (for example, R2535X) increases the
severity of bleeding within a given family.18 In these
families, simple heterozygotes show only minor
bleeding symptoms.18 However, in most cases with
variable penetrance the genetic molecular back-
ground has not yet been investigated. In some of
these families, linkage studies failed to establish a
relation between the phenotype and a given VWF
allele.22 In these cases, a number of genetic and
non-genetic factors are likely to contribute to the
wide variability of the clinical and laboratory phe-
notype.23
About 60% of the variation in VWF plasma is due
to genetic factors, with ABO group accounting for
only about 30%.24 In type O subjects the VWF lev-
el is 25-35% lower than in non-O individuals.25
Thus, other unknown genetic factors may greatly
influence VWF levels and, taken together with ABO
Table 3. List of the most frequent mutations in type 2A, 2B,
2M and 2N disease according to VWF domains.
Localization of VWD types VWF mutations associated with specific types
VWF defects 1
D2 domain Type 2A F404insNP R436del6 N528S G550R 
(formerly IIC) C623W A625insG
D’ – D3 domains Type 2N R782W G785E E787K C788R
C788Y T791M Y795C M800V
R816W R816Q H817Q R854Q
R854W C858F D879N Q1053H
C1060R C1225G
D3 domain Type 2M R1205H Y1146C
(formerly 1 Vicenza)
Type 2A C1143Y C1173R
(formerly IIE)
A1 domain Type 2B P1266L H1268D C1272G C1272R 
(formerly IIB) M1304insM R1306Q R1306L R1306W
R1308C R1308P I1309V S1310F 
W1313C V1314F V1314L V1316M
P1337L R1341L R1341Q R1341W
L1460V A1461V
Type 2M G1324S G1324A E1359K F1369I
I1425F Q1191del1 K1408delK
Type2M/2A L1276P R1374C R1374H C1458Y
R1374R
A2 domain Type 2A G1505E G1505R S1506L F1514C
(formerly IIA) K1518E L1540P S1543F Q1556R
L1562P R1597G R1597Q R1597W
V1604F V1607D V1609R P1627H 
I1628T G1629R V1630F E1638K
L1639P P1648S L1657I V1665E
G1672R
CK domain Type 2A C2773R
(formerly IID)
For an updated list of VWF mutations according to VWD types, the web site:
www.shef.ac.uk/vwf  can be checked.
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blood groups and environmental effects, help
explain the wide variety and incomplete pene-
trance of type 1 VWD. Furthermore, at least one
subset of type 1 may have a combination of genet-
ic modifier mutations outside the VWF gene thus
accounting for the failure of linkage studies. A pos-
sible example has been provided by a murine mod-
el of VWD, the RIIIS/J inbred mouse strain.26 Using
a positional cloning approach, the authors suc-
ceeded in identifying Mvwf as the unique allele for
a previously known glycosyltransferase gene Gal-
gt2. Galgt2 is expressed primarily in the gut epithe-
lium. Although its function in this tissue is
unknown, gut specific expression is conserved in
humans, suggesting an important role for the cor-
responding post-translational modification.
Since many aspects of type 1 VWD abnormalities
are still not understood, a specific project entitled
Molecular and Clinical Markers for Diagnosis and
Management of Type 1 VWD was organized and
sponsored by the European Union and the first
results will be available within 2003.
In type 3 VWD, besides the mechanisms possibly
shared with some type 1 cases (see above), partial
or total gene deletions have been reported.12
Notably, homozygosity for gene deletion may be
associated with the appearance of allo-antibodies
against VWF, which may render replacement ther-
apy ineffective and stimulate anaphylactic reactions
to treatment.12 In general, mutations may be scat-
tered over the entire gene, but some (e. g. 2680delC
or Arg2535X) are particularly recurrent in Northern
Europe.12 The coding region of the VWF gene con-
tains 11 CGA codons (Arg). CG-dinucleotides are hot
spots for mutation and a C to T mutation will result
in a stop codon. Stop codons, in either homozygos-
ity or compound heterozygosity, have been report-
ed in exons 9, 28, 32 and 45.27 Gene defects of type
3 VWD patients from three different populations
have now been studied,28 but there was  no founder
effect and mutations were distributed throughout
the entire VWF gene (Figure 2).
Prevalence and frequency of subtypes of
von Willebrand’s disease
VWD is the most frequent inherited bleeding dis-
order. Until the late 1980s, its prevalence was esti-
mated from the number of patients registered at
specialized centers. This approach gave an esti-
mated prevalence ranging from 4 to 10 cas-
es/100,000 inhabitants.29-32 Bloom and Giddins in
1991, using the results obtained by a questionnaire
sent to Hemophilia Centers worldwide,31 gave an
adjusted prevalence ranging from 0.37 to 23.9 cas-
Figure 2. Distribution of
the mutations found in the
VWF coding region report-
ed along with the homolo-
gous repeat domain struc-
ture. Note that no specif-
ic cluster for mutations is
found in type 3 VWD as
reported by Baronciani et
al.28 
Table 4. Prevalence of VWD: analysis of population studies.
Study Methodology Population Prevalence
Rodeghiero et al.34 History + VWF:RCo Caucasian children 0.82 %
Family study (0.57 - 1.15)*
Rodeghiero et al.35 As above + VWF:Ag As above 0.7 %
instead of VWF:RCo
Miller et al.36 VWF:RCo Adult blood donors 1.6 %
(0.2 % bleeder)
Meriane et al.37 History + VWF:RCo Arabic - Turkish 1.23 %
Family study Adult students
Werner et al.38 History + VWF:RCo Caucasian - Black 1.3 %
Family study children (1.15 %
Caucasian)
1.81 % Black)
*Prevalence taking into account the 90 % confidence interval for the lower limit
of normal range.
es/100,000 population (Scandinavia). It is general-
ly assumed that the number of people with symp-
tomatic VWD requiring specific treatment, would
be at least 100 per million.33 Only a few studies
have set out to estimate the prevalence of VWD by
screening small populations using formal, stan-
dardized criteria. Table 4 summarizes the main
characteristics of these studies.34-38 In fact, the
prevalence approaches 1% without ethnic differ-
ences. However, the large majority of cases diag-
nosed in population studies appear to have mild
disease, and most of these subjects had not had
any detailed hemostatic evaluation before.
It remains to be known whether these cases are
due to mutations within the VWF gene or are the
effect of an outside gene that influences the cir-
culating level of VWF. Extensive haplotype studies
or the demonstration, as in murine VWD,26 of the
effect of another gene are needed to clarify this
issue. Table 5 summarizes the main reported
series.39-43 These estimates are obviously biased
since many type 1 VWD cases without major symp-
toms are presumably not reported and almost all
severe type 3 VWD are followed at specialized cen-
ters. Probably, however, the prevalence of type 3 is
underestimated since the figures on this subtype
were based mainly on mail surveys to leading
hemophilia centers, with ill-defined inclusion cri-
teria. In contrast, in population studies almost all
cases were type 1,35,39 providing further confirma-
tion that mild cases are probably underestimated
in series from specialized centers.
In the past the most frequent form of VWD was
considered to be type I.39-43 A recent retrospective
study based on reappraisal of type 1 diagnoses
after ten years (1992 versus 2002) in 316 VWD
patients followed in a single Hemophilia Center,
found that the numbers with types 3, 2A, 2B, 2N
remained the same. Among the 215 (69%) type 1
VWD cases previously diagnosed, however, only 108
(34%) were confirmed as type 1. A total of 105 case
(33%) showed abnormal VWF activity, as shown by
a VWF:RCo/Ag ratio < 0.7.44
Clinical manifestations
The clinical expression of VWD is usually mild in
type 1, the severity increasing in types 2 and 3.
However, in some families the severity of bleeding
manifestations varies, underlining the different
molecular bases of the diverse phenotypes of this
disorder, and its variable penetrance. In general,
the severity of bleeding correlates with the degree
of the reduction of FVIII:C, but not with the mag-
nitude of BT prolongation or with the patient’s ABO
blood type.
Mucocutaneous bleeding (epistaxis, menorrha-
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Table 7. Clinical and laboratory parameters used for VWD
diagnosis.
Patients at risk of VWD
Clinical history: lifelong mucocutaneous and postoperative bleeding.
Symptoms are sometimes present in other family members.
Screening tests: prolonged bleeding time (maybe normal); normal platelet count;
prolonged PTT (maybe normal).
Diagnosis and definition of VWD type
VWF antigen [a]
VWF: Ristocetin cofactor activity [b]
Factor VIII [c]
VWF multimeric structure on low resolution gels [e]
Diagnosis of VWD subtype 
Ristocetin-induced platelet agglutination (RIPA) [d]
VWF multimeric structure on high resolution gels [e]
Platelet VWF content [f]
Factor VIII binding assay [g]
For the use of these tests see the diagnostic flow-chart reported in Figure 3 and
also.50
Table 5. Frequency of subtypes of von Willebrand’s disease.
Authors Number of patients Type 1 (%) Type 2 (%) Type 3 (%)
Tuddenham39 134 75 19 6
Lenk et al.40 111 76 12 12
Nillson31 106 families 70 10 20
Hoyer et al.41 116 71 23 6
Awidi42 65 59 29.5 11.5
Berliner et al.43 60 62 9 29
Table 6. Incidence (%) of  bleeding symptoms in patients
with VWD and in normal subjects (adapted from Lak et al.;48
Silwer;49 Federici et al.).50
Iranian VWD Italian VWD(*) Scandinavia
(n = 1234)
Symptoms Type 3 Type 1 Type 2 Type 3 VWD Normals
(n = 348) (n = 618) (n = 550) (n = 66) (n= 264) (n = 500)
Epistaxis 77 61 63 66 62 5
Menorrhagia 69 32 32 56 60 25
Post-extraction bleeding 70 31 39 53 51 5
Hematomas n. r. 13 14 33 49 12
Bleeding from minor wounds n. r.. 36 40 50 36 0.2
Gum bleeding n. r.. 31 35 56 35 7
Post-surgical bleeding 41 20 23 41 28 1
Post-partum bleeding 15 17 18 26 23 19
Gastrointestinal bleeding 20 5 8 20 14 1
Joint bleeding 37 3 4 45 8 0
Hematuria 1 2 5 12 7 1
Cerebral bleeding n. r. . 1 2 9 n. r 0
n. r.: not reported; (*) Bleeding symptoms in Italian patients have been recently
recalculated according to the updated results of the Italian Registry of VWD and
are, therefore different from previously reported.50
gia) is a typical manifestation of the disease and
may even affect the quality of life. VWD may be
highly prevalent in patients with isolated menor-
rhagia.45 Women with VWD may require treatment
with antifibrinolytics, iron supplementation or an
estroprogestinic pill to control heavy menses.
Bleeding after dental extraction is the most fre-
quent post-operative bleeding manifestation. Since
FVIII is usually only slightly reduced, manifesta-
tions of a severe coagulation defect (hemarthrosis,
deep muscle hematoma) are rare in type 1 VWD
and are mainly post-traumatic, whereas in type 3
the severity of bleeding may sometimes resemble
that in patients with hemophilia. Bleeding after
delivery is rare in type 1 VWD since FVIII/VWF lev-
els tend to become normal at the end of pregnan-
cy.46 In a few cases, however, the FVIII/VWF levels
do not become normal and these women need pro-
phylaxis with DDAVP or factor VIII/VWF concen-
trates (see later) before delivery.47 Women with
type 2A, 2B and 3 VWD disease usually need
replacement therapy post-partum to prevent
immediate or late bleeding.48 Post-operative bleed-
ing may not occur even in more severely affected
type 1 VWD patients, but in type 3 VWD prophy-
laxis is always required.
To date, only a few full descriptions of symptoms
in VWD patients have been provided48-50 and only
one study took into account the differentiation
according to the VWD types.50 Table 6 shows the
relative frequency of bleeding symptoms in three
large series of patients with VWD diagnosed at spe-
cialized centers. In the Scandinavian experience,
the percentage of patients with post-partum
bleeding overlapped the percentage observed in
normal females. It is striking that the distribution
of different types of bleeding (apart from joint
bleeding) is similar for the different subtypes. How-
ever, the severity of bleeding manifestations (for
example menorrhagia or gastrointestinal bleeding)
is more marked in type 3 VWD, often requiring
replacement treatment. Guidelines for the diagno-
sis and therapy of VWD in Italy have recently been
published50 and some data will also be discussed in
this review.
Diagnosis of von Willebrand disease
The spectrum of severity of VWD is wide, ranging
from few, doubtful hemorrhagic symptoms to
severe life-threatening bleeding episodes. This is
due not only to the heterogeneous defects of the
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Table 8A. Basic and discriminating laboratory assays for
the diagnosis of VWD.
Test Pathophysiologic significance Diagnostic significance
Ristocetin Cofactor VWF-GpIbα interaction as Functional test; most 
(VWF:RCo) using mediated by ristocetin in vitro sensitive screening test
formalin-fixed platelets (ristocetin at fixed concentration,
and fixed ristocetin normal platelets, patient plasma)
concentration (1 mg/mL)53
Immunologic assay Antigen concentration Correlates with VWF:RCo
with polyclonal in type 1; reduced ratio 
antibody (VWF:Ag)52 VWF:RCo/Ag suggests 
type 2 VWD
FVIII:C level FVIII/VWF interaction Not specific, but useful
(one-stage assay) for patient management
Bleeding time Platelet-vessel wall Not specific;correlates 
(Ivy method) VWF-mediated interaction with platelet VWF content
in type 1 VWD. Screens
for qualitative platelet 
defects.
Ristocetin-induced Threshold of ristocetin Allows discrimination  
platelet aggregation concentration inducing from type 2B,
(RIPA) patient platelet-rich characterized
plasma  aggregation by reduced threshold
Multimeric analysis Multimeric composition Presence of full range of
of VWF multimers in types 1, 2M,
2N. Loss of high and
intermediate multimers
in types 2A and 2B.
Platelet VWF Reflects also endothelial stores Useful to predict
responsiveness
to desmopressin in type 1
Binding of FVIII  to VWF Interaction of normal FVIII Allows discrimination
with patient’s plasma VWF from type 2N,
characterized by
low binding values
Table 8B. Other tests proposed for VWD diagnosis.
Test Pathophysiologic significance Diagnostic significance
Binding of VWF VWF-collagen interaction Correlates with VWF :RCo in type 
to collagen60 1 VWD; some collagen
preparations more sensitive
to high molecular weight
multimers61,62
Closure time Simulates primary More sensitive than bleeding
PFA-10058,59 hemostasis after time in screening for VWD;
injury to a small not tested in bleeding subjects
vessel without specific diagnosis;
specificity unknown; more data 
needed before recommendation
for clinical laboratory
Monoclonal Moab against an epitope Correlation with VWF:RCo not
antibody-based of VWF involved in the confirmed; not suggested instead
ELISA54 interaction with GpIbα of VWF:RCo55
Elisa-based Measures interaction Promising new test to use
VWF:RCo56 between VWF instead of VWF:RCo; more
and captured rGpIbα data needed
fragment in the presence
of ristocetin
Moab: monoclonal antibodies.
VWF gene which may impair its hemostatic func-
tion, but also to the influence exerted by other
genes (e.g., those for ABO blood groups). In addition,
many acquired conditions, either physiologic (stress,
pregnancy) or pathologic (inflammation), can
induce fluctuations in VWF levels. Thus, the diag-
nosis of VWD, particularly type 1, may require sev-
eral laboratory tests.
Screening tests. These tests are usually applied
for patients with a suspected bleeding tendency
and Table 7 summarizes the different steps for diag-
nosing VWD. The platelet count is usually normal,
but mild thrombocytopenia may occur in patients
with type 2B VWD. The bleeding time (BT) is usual-
ly prolonged, though it may be normal in patients
with mild forms of VWD such as those with type 1
and normal platelet VWF content.51 The prothrom-
bin time (PT) is normal whereas the partial throm-
boplastin time (PTT) may be  prolonged to a variable
degree, depending on the plasma FVIII levels.
Diagnosis of VWD and identification of the type.
The list of tests used to diagnose VWD and their
pathophysiologic and diagnostic significance are
reported in Table 8a.52,53 VWF antigen (VWF:Ag) is
unmeasurable in type 3 VWD, whereas it may be
low in type 1 and low or normal in type 2. The assay
for ristocetin cofactor activity (VWF:RCo) explores
the interaction of VWF with platelet GPIbα and is
still the standard method for measuring VWF activ-
ity. It is based on the property of the antibiotic ris-
tocetin to agglutinate formalin-fixed normal
platelets in the presence of VWF. Besides the orig-
inal method,53 new ex vivo methods have been pro-
posed to measure the interactions between VWF
and its platelet receptors in the presence of risto-
cetin, as reported in Table 8b.54-56
In patients with a normal VWF structure (type 1
VWD), VWF:RCo values are similar to VWF:Ag.  Lev-
els lower than VWF:Ag (VWF:RCo/Ag ratio < 0.7) are
characteristic of type 2 VWD, as recently reported
in the guidelines for diagnosis and treatment of
VWD in Italy.50 FVIII:C plasma levels are very low
(1-5 %) in patients with type 3 VWD. In patients
with type 1 or type 2 VWD, FVIII may be decreased
to a variable extent but is sometimes normal.
Normal VWF is composed of a complex series of
multimers with molecular weight ranging from 800
to 20,000 kDa, which can be analyzed by agarose
gel electrophoresis. Low-resolution agarose gels
distinguish VWF multimers, which are convention-
ally indicated as high, intermediate and low mole-
cular weight. In types 1, 2M and 2N VWD all mul-
timers are present, whereas in types 2A and 2B the
high and intermediate multimers are missing.
Diagnosis of the subtype. For a correct diagnosis
of patients with VWD and to establish their treat-
ment, other assays are used to define specific sub-
types. Ristocetin-induced platelet agglutination
(RIPA) is measured by mixing different concentra-
tions of ristocetin and the patient’s platelet rich-
plasma (PRP) in an aggregometer. Results are
expressed as the concentrations of ristocetin
(mg/mL) able to induce 30% agglutination. Most
VWD types and subtypes show a low response to
ristocetin, but an important exception is type 2B
VWD, in which there is hyperresponsiveness to ris-
tocetin, due to a higher than normal affinity of VWF
for platelet GPIbα.57
VWF multimeric analysis with high-resolution
agarose gels identifies VWD subtypes 1 and 2 bet-
ter. Platelet VWF plays an important role in prima-
ry hemostasis, since it can be released from α-gran-
ules directly to the site of vascular injury. On the
basis of its measurement, type 1 VWD can be clas-
sified in three subtypes: type 1 platelet normal,
with a normal content of functionally normal VWF;
type 1 platelet low, with low concentrations of
functionally normal VWF; type 1 platelet discor-
dant, with normal concentrations of dysfunctional
VWF.51
The factor VIII binding assay measures the affin-
ity of VWF for FVIII. In this assay, anti-VWF anti-
body is coated on wells of a microtiter plate and
test plasma is added to the wells. The factor VIII/WF
complex from the plasma is bound by the antibody
after which factor VIII is removed from the complex
by a high ionic strength buffer. Excess recombi-
nant FVIII (rFVIII) is then added and, after removal
of unbound rFVIII, the VWF and the bound rFVIII are
assayed. This assay allows type 2N VWD to be dis-
tinguished from mild to moderate hemophilia A.
Diagnostic approach. The diagnosis of VWD sub-
types can be made by using the methods described
above, in the flow-chart already proposed in the
guidelines for diagnosis and treatment of VWD in
Italy (Figure 3). Type 3 VWD can be diagnosed in
cases of unmeasurable VWF:Ag. A proportionate
reduction of both VWF:Ag and VWF:RCo with a
RCo/Ag ratio > 0.7 suggests type 1 VWD. If the
VWF:RCo/Ag ratio is < 0.7 type 2 disease is diag-
nosed. Type 2B VWD can be identified by an
enhanced RIPA (< 0.8 mg/mL) while type 2A and
2M cause low RIPA  (> 1.2 mg/mL). Multimeric
analysis in plasma is necessary to distinguish
between type 2A VWD (lack of the largest and
intermediate multimers) and type 2M VWD (all the
multimers present as in normal plasma). Type 2N
VWD can be suspected in the case of discrepant
values for factor VIII and VWF:Ag (ratio <1) and
diagnosis should be confirmed by the specific test
of VWF:factor VIII binding capacity (VWF:FVIIIB).
In type 1 VWD the ratio between factor VIII and
VWF:Ag is always > 1 and the severity of type 1
VWD phenotype can usually be evaluated from
platelet VWF measurements.50
Additional tests for VWD diagnosis include the
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closure time (CT) and assays of VWF activity based
on binding to collagen (VWF:CB). The CT can be eval-
uated with the Platelet Function Analyzer (PFA-
100), which gives a rapid and simple measure of
VWF-dependent platelet function at high shear
stress. This system is sensitive and reproducible for
VWD screening, even though the CT is normal in
type 2N disease.58,59 Assays are also available for
VWF:CB and the ratio of VWF:CB to VWF:Ag appears
to be useful for distinguishing types 1 and 2.60-62
Neither assay has been well standardized yet and
thus are not officially approved by the Scientific
Standardization Committee on VWF of the Interna-
tional Society of Thrombosis and Haemostasis.
Management of patients with VWD
The goal of therapy in patients with VWD is to
correct the dual defect of hemostasis, i.e. the abnor-
mal platelet adhesion and the abnormal intrinsic
coagulation pathway due to low FVIII levels. There
are two treatments of choice, desmopressin or
transfusional therapy with blood products. Other
forms of treatment can be considered as adjunctive
or alternatives to these.63,64
Desmopressin
Desmopressin (1-deamino-8-D-arginine vaso-
pressin, DDAVP) is a synthetic analog of vaso-
pressin originally designed for the treatment of
diabetes insipidus. DDAVP raises FVIII and VWF
plasma concentrations with no major side effects
in healthy volunteers or patients with mild hemo-
philia and VWD.65 Its mechanism of action has
been recently investigated.66 The first successful
clinical trial with DDAVP was in 1977, its aim being
to avoid the use of blood products in mild hemo-
philia and VWD patients who needed dental
extractions and other surgical procedures.67 Fol-
lowing these early observations, DDAVP has been
widely used for the treatment of these diseases.68
The obvious advantages is that DDAVP is relative-
ly inexpensive and carries no risk of transmitting
blood-borne viruses. DDAVP is usually infused
intravenously over 30 minutes at a dose of 0.3
mg/Kg diluted in 50 mL saline. This increases plas-
ma FVIII/VWF 3 to 5 times above the basal levels
within 30-60 minutes and, in general, high FVI-
II/VWF concentrations last for 6 to 8 hours.
Since the responses in a given patient are con-
sistent on different occasions,69 a test dose of
DDAVP at the time of diagnosis helps to establish
the individual response patterns. Infusions can be
repeated every 12 to 24 hours depending on the
type and severity of the bleeding episode. Howev-
er, most patients treated repeatedly with DDAVP
become less responsive to therapy.70 The drug is
also available in concentrated forms for subcuta-
neous and intranasal administration, which can be
convenient for home treatment.71
The protocol of the DDAVP infusion test with the
clinical and laboratory parameters used to assess
the biological response in each patient are sum-
marized in Table 9; the definition of response to
DDAVP is also reported together with the list of
DDAVP products commercially available in Italy.50
Side effects of DDAVP are usually mild tachycar-
Figure 3. Diagnostic flow chart of dif-
ferent VWD types. Type 3 VWD can be
diagnosed in case of unmeasurable
VWF:Ag (a). A proportional reduction of
both VWF:Ag and VWF:RCo with a
RCo/Ag ratio > 0.7 suggests  type 1
VWD (b).  If the VWF:RCo/Ag ratio is <
0.7 type 2 is diagnosed. Type 2B VWD
(d) can be identified in case of an
enhanced RIPA (< 0.8 mg/mL) while
type 2A and 2M cause low RIPA (> 1.2
mg/mL). Multimeric analysis in plasma
(e) is necessary to distinguish between
type 2A VWD (lack of the largest and
intermediate multimers) and type 2M
VWD (all the multimers present as in
normal plasma). Type 2N VWD can be
suspected in case of discrepant values
for factor VIII (c) and VWF:Ag (ratio <1)
and diagnosis should be confirmed by
the specific test (g) of VWF:factor VIII
binding capacity (VWF:FVIIIB). In type
1 VWD the ratio between factor VIII and
VWF:Ag is always > 1;the severity of
type 1 VWD phenotype can usually be
evaluated from platelet VWF (f) mea-
surements.50 See also Tables 7 and 8A.
dia, headache and flushing: these are attributed to
the vasomotor effects of the drug and can often be
attenuated by slowing the rate of infusion. Hypona-
tremia and volume overload due to the anti-diuret-
ic effects of DDAVP are relatively rare. A few cases
have been described, mostly in young children who
received closely repeated infusions.71 Though no
thrombotic episodes have been reported in VWD
patients treated with DDAVP, this drug should be
used with caution in elderly patients with athero-
sclerotic disease, because a few cases of myocardial
infarction and stroke have occurred in hemophiliacs
and uremic patients given DDAVP.73,74 DDAVP is most
effective in patients with type 1 VWD, especially
those who have normal VWF in storage sites (type
1, platelet normal).51,75 In these patients FVIII, VWF
and the BT are usually corrected within 30 minutes
and remain normal for 6-8 hours. In other VWD sub-
types, responsiveness to DDAVP varies. The response
is poor and  short-lasting in type 1, platelet low.51 In
type 2A VWD, FVIII levels are usually raised by
DDAVP but the BT is shortened in only a minority of
cases.76 Desmopressin is contraindicated in type 2B
VWD, because of the transient appearance of
thrombocytopenia.77 However, there have been
reports on its clinical usefulness in some 2B cases.78
In any case, the platelet count should be checked
during test-infusion to detect any non-classical type
2B cases with thrombocytopenia occurring after
infusion.79 In type 2N relatively high levels of FVIII
are obtained after DDAVP, but released FVIII circu-
lates for a shorter time in plasma because the sta-
bilizing effect of VWF is impaired.80 Patients with
type 3 VWD are usually unresponsive to DDAVP.
However, a subgroup of patients with severe reces-
sive VWD has been reported, characterized by nor-
malization of FVIII without any changes of the
abnormal BT.81 Interestingly, all these patients share
a unique mutation (C2362F) in compound het-
erozygosity or homozygosity.20
Other non-transfusional therapies for VWD
Two other non-transfusional therapies are used
in the management of VWD: antifibrinolytic amino
acids and estrogens. Antifibrinolytic amino acids are
synthetic drugs that interfere with the lysis of new-
ly formed clots by saturating the binding sites on
plasminogen, thereby preventing its attachment to
fibrin and making plasminogen unavailable within
the forming clot. Epsilon xaminocaproic acid (50
mg/Kg four times a day) and tranexamic acid (15-
25 mg/kg three times a day) are the most frequent-
ly used antifibrinolytic amino acids. Both can be
administered orally, intravenously or topically and
are useful alone or as adjuncts in the management
of oral cavity bleeding, epistaxis, gastrointestinal
bleeding and menorrhagia. Being drugs that inhib-
it the fibrinolytic system, they carry a potential risk
of thrombosis in patients with an underlying pro-
thrombotic state. They are also contraindicated in
the management of urinary tract bleeding.
Estrogens raise plasma VWF levels, but the
response is variable and unpredictable, so they are
not widely used for therapeutic purposes. It is com-
mon clinical experience that the continued use of
oral contraceptives is very useful in reducing the
severity of menorrhagia in women with VWD, even
in those with type 3, despite the fact that FVIII/VWF
levels are not modified.
Transfusional therapies
Transfusional therapy with blood products con-
taining FVIII/VWF is at the moment the treatment of
choice for patients unresponsive to DDAVP.63, 64 Ear-
ly studies indicated that cryoprecipitate every 12-24
hours normalized plasma FVIII levels, shortened the
BT and stopped or prevented clinical bleeding in
VWD. Based on these observations cryoprecipitate
has been the mainstay of VWD therapy for many
years. However, in 1992 the analysis of published
reports pointed out that the BT is not always cor-
rected following cryoprecipitate.82
Virucidal methods cannot be applied to cryopre-
cipitate, so it carries a small but definite risk of
transmitting blood-borne infections. Therefore,
virus-inactivated concentrates, originally developed
for the treatment of hemophilia A, play an important
role in the current management of VWD patients
unresponsive to DDAVP. Concentrates obtained by
immunoaffinity chromatography on monoclonal
antibodies (FVIII >2,000 IU/mg) contain very small
amounts of VWF and are therefore unsuitable for
VWD management. A chromatography-purified con-
centrate particularly rich in VWF and with a very
low content of FVIII has also been produced; it is
called very-high purity VWF concentrate.83 It was
effective in a small cohort of type 3 VWD cases.84 The
very low content of FVIII in this concentrate some-
times makes it necessary, for the treatment of acute
bleeding episodes and for emergency surgery, to
infuse VWD patients also with a single first dose of
purified FVIII concentrate to ensure immediate cor-
rection of the low FVIII levels.
No further use of FVIII concentrate is required lat-
er on, because the infused VWF triggers the endoge-
nous synthesis of FVIII with normalization of FVIII
levels after 6-8 hours. This might offer an example
for the near future of a more specific therapeutic
approach, as proposed by some French hematolo-
gists.85 The dosages of concentrates recommended
for the control of bleeding episodes are summa-
rized in Table 11. The characteristics of products
containing FVIII/VWF commercially available in
Italy, partially modified from those reported in the
Guidelines for diagnosis and therapy of VWD in
Italy, are summarized in Table 10.50 Since commer-
cially available intermediate and high-purity FVI-
II/VWF concentrates contain large amounts of FVI-
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II and VWF, high post-infusion levels of these moi-
eties are consistently obtained.86-88 There is also a
sustained rise in FVIII, higher than predicted from
the doses infused, lasting up to 24 hours. This pat-
tern is due to the stabilizing effect of exogenous
VWF on endogenous FVIII, which is synthesized at
a normal rate in these VWD patients.89
The accumulation of exogenous FVIII infused with
the concentrates, together with that endogenously
synthesized and stabilized by the infused VWF, caus-
es very high FVIII levels when multiple infusions are
given for severe bleeding episodes or to cover major
surgery. There is some concern that sustained high
levels of FVIII may increase the risk of post-opera-
tive deep vein thrombosis as recently suggested by
several epidemiological studies.90-92 Rare episodes
of deep vein thrombosis have been reported in
patients with VWD receiving repeated infusions of
FVIII/VWF concentrates to maintain clinical hemo-
stasis after surgery.93-95
These FVIII/VWF products are not always effec-
tive in correcting the BT96 and there are probably
various reasons for this. So far, no concentrate con-
tains a completely functional VWF, as assessed in
vitro by evaluating the multimeric pattern and
using several functional assays, because VWF pro-
teolysis occurs during purification due to the action
of platelet and leukocyte proteases contaminating
plasma used for fractionation.97 It must borne in
mind that the ideal exogenous FVIII/VWF concen-
trate with all its functional activities and all mul-
timers can never correct the VWF defects in the
subendothelium and in the platelets of VWD
patients. On the other hand, in clinical practice,
despite their limited and inconsistent effect on BT,
FVIII/VWF concentrates are successfully used for
the treatment of VWD patients unresponsive to
DDAVP, especially for those with soft-tissue and
post-operative bleeding.82
When the BT remains long and bleeding persists
Table 9. Products containing desmopressin commercially
available in Italy.
Products Preparation Volume/ Number of Comments
(Company) ampoule ampoules/pack
Emosint 4 µg 0.5 mL 10 Concentrated ampoules
(Kedrion) 20 µg 1 mL 10 can be administered also
40 µg 1mL 10 subcutaneously
Minirin DDAVP 4 µg 1 mL 10
(Ferring/Valeas)
Infusion Test with Desmopressin
Infusion protocol Administer in 30 minutes 0.3 µg/Kg of
desmopressin in 50 mL of saline.
The same dosage can also be administered
subcutaneously.
Clinical and laboratory parameters Factor VIII/VWF activities must be measured
before and 0.5, 1, 2 and 4 hours after the
administration of desmopressin; bleeding
time must be measured at least before and
after 2 hours. Check platelet count before and
at least 2 hours after infusion
Definition of responsiveness VWD patients should be considered
responsive to desmopressin if after 2 hours
they show at least 3-fold increases of baseline 
levels of FVIII:C and VWF:RCo, with levels of
at least 30 U/dL and a bleeding time of
12 minutes or less, when prolonged.
Table 10. Characteristics of products containing FVIII/VWF
commercially available in Italy.
Products Purification Viral Specific VWF:RCo/ VWF:RCo/ Other
(Company) Inactivation activity* Ag° FVIII° proteins
(U/mg prot) (Ratio) (Ratio)
AlphaNate Affinity Solv./Det. + >100 0.94 1.21 Albumin +
(Alpha Chromatography 72 hrs at
Ther) (Heparin) 80°C
Emoclot D.I. Ion Exchange Solv./Det. + ≥ 80 0.61 1.16 Albumin -
(Kedrion) Chromatography 30 min. a
100°C
Fanhdi Affinity Solv./Det. + >100 0.83 1.48 Albumin +
(Grifols) Chromatography 72 hrs at
(Heparin) 80°C
Haemate P Multiple Pasteurization 40±6 0.96 2.54 Albumin +
(Aventis Precipitation 10 hrs at 
Behring) 60°C 
Immunate Ion Exchange Det. + 
(Baxter) Chromatography Vapour heat 100±50 0.47 1.10 Albumin +
10 h at 60°,
1h at 80°
*Specific activity measured as FVIII before adding albumin as stabilizer.°
VWF:RCo values are not available in the technical description of all concentrates:
therefore only the mean values calculated by producers on different concentrate
stocks could be reported.
Table 11. Doses of factor VIII-VWF concentrates  recom-
mended in VWD patients unresponsive to DDAVP.
Type of bleeding Dose Number of Objective
(IU/kg) Infusions
Major surgery 50 Once a day  or Maintain factor VIII
every other day > 50 U/dL for at least
7 days
Minor surgery 30 Once a day or factor VIII >30 U/dL
every other day for at least 5-7 days
Dental extractions 20-40 Single factor VIII >30 U/dL
for up to 6 hours
Spontaneous or 20-40 Single
post-traumatic bleeding
despite replacement therapy, other therapeutic
options are available. DDAVP given after cryopre-
cipitate further shortened or normalized BT in
patients with type 3 VWD in whom cryoprecipitate
had failed to correct the BT.98 Platelet concentrates
(given before or after cryoprecipitate, at doses of
4-5×1011 platelets) achieved similar effects, in
terms of both BT correction and bleeding control,
in patients unresponsive to cryoprecipitate alone.99
These data emphasize the important role of platelet
VWF in establishing and maintaining primary
hemostasis. The therapeutic approaches according
to VWD subtypes are summarized in Table 12.
Treatment of patients with allo-antibodies
to VWF
For the rare patients with type 3 VWD who devel-
op anti-VWF allo-antibodies after multiple trans-
fusions, infusion of VWF concentrates not only is
ineffective, but may even cause post-infusion ana-
phylaxis due to the formation of immune com-
plexes.100-102 These reactions may be life-threaten-
ing.103,104 To overcome this drawback, a patient
undergoing emergency abdominal surgery was
treated with recombinant FVIII, because this prod-
uct, which contains no VWF, could not cause ana-
phylactic reactions. In view of the very short half-
life of FVIII without its VWF carrier, recombinant
FVIII had to be administered by continuous i. v.
infusion, at very large doses, to keep FVIII levels
above 50 U/dL for 10 days after surgery.104
Conclusions
VWD is the most frequent inherited bleeding dis-
order. The prevalence of clinically relevant VWD
has not been estimated directly in the population,
but a figure around 100 cases/million people, sim-
ilar to that of hemophilia A, is widely accepted. The
phenotypic diagnosis is still the most accessible on
account of the difficulties and costs of molecular
diagnosis. However, molecular diagnosis can be
useful to confirm specific VWF defects in VWD
families. It is still not clear whether most mild type
1 VWD patients really have a mutation in the VWF
locus. The results of a large multicenter European
Study entitled Molecular and Clinical Markers for
Diagnosis and Management of type 1 VWD, involv-
ing 150 VWD families, will soon be available and
should provide insight into these issues. Despite its
complex and heterogeneous nature, nowadays
VWD can be efficiently and safely treated and mor-
tality is virtually zero in Western countries.
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